(Q36779557)

English

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

scientific article published on 28 March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

1

object named as

Fred C Tenover

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

author name string

Robert C Moellering

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

language of work or name

0 references

publication date

28 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1208-1215

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Vancomycin-resistant Staphylococcus aureus: infection control considerations

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Vancomycin-resistant Staphylococcus aureus: no apocalypse now

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1086%2F513203

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36779557&oldid=1656043472"